Notice/News
Notice/News
The external news articles in this bulletin have been collected and published solely for the purpose of providing information and may differ from our official position. We make no guarantee of the accuracy, timeliness, or completeness of the content of the article and are not liable for any direct or indirect damage that may occur.
Number
Title
Date
1
ToolGen Opens Global Gene-Edited Seed LMO Field at Osong Innovation Center, Targets SAF and Industrial Crop Markets
2026.06.11
2
[The Bio] ToolGen to Leverage Financial Strength in Global Gene-Editing IP Battle
2026.06.01
3
[IR Pharm] A New Paradigm in Gene Editing③: The Aesthetics of Paradox: The Longer the Dispute, the Deeper the ‘Monopoly’… ToolGen’s IP Monetization Strategy
2026.05.06
4
[IR Pharm] A New Paradigm in Gene Editing②: From the Lab to the Courtroom… Opening Salvo in the IP Battle to Determine Ownership of ‘CRISPR Tolls’
2026.05.05
5
[IR Pharm] A New Paradigm in Gene Editing①: The End of Statistics, the Age of Mechanisms… An Unprecedented Opportunity for ToolGen Amid FDA Regulatory Revolution
2026.05.04
6
[Notice] U.S. Patent Registration Certificate (US 12,612,632 / US 12,612,633 / US 12,612,634)
2026.04.28
7
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.28
8
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.04.21
9
[Notice] U.S. CRISPR RNP Patent Granted_US 12,606,832 B2
2026.04.21
10
[Notice] The Priority Phase of Interference No. 106,126 between ToolGen and the Broad Institute has resumed
2026.03.31
11
[Notice] March 26, 2026 PTAB Decision: Summary and Outlook
2026.03.30
12
[edaily] “ToolGen’s Yoo Jong‑sang Says CRISPR‑Cas9 Patent Battle Heats Up in H2, With Rising Pressure for a Three‑Party Deal”
2026.03.26
13
[Notice] ToolGen to Form Science Advisory Board (SAB)
2026.03.25
14
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.03.18
15
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18